Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent

Meredith, Ian T; Verheye, Stefan; Dubois, Christophe; Dens, Joseph; Fajadet, Jean; Carrié, Didier; Walsh, Simon; Oldroyd, Keith G; Varenne, Olivier; El-Jack, Seif; Moreno, Raul; Joshi, Anita A; Allocco, Dominic J; Dawkins, Keith D

doi:10.1016/j.jacc.2011.12.016

Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent

Author:

Meredith, Ian T

Verheye, Stefan ; Dubois, Christophe ; Dens, Joseph ; Fajadet, Jean ; Carrié, Didier ; Walsh, Simon ; Oldroyd, Keith G ; Varenne, Olivier ; El-Jack, Seif ; Moreno, Raul ; Joshi, Anita A ; Allocco, Dominic J ; Dawkins, Keith D

Keywords:

Absorbable Implants, Angioplasty, Balloon, Coronary, Coated Materials, Biocompatible, Coronary Angiography, Coronary Artery Disease, Drug-Eluting Stents, Electrocardiography, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, Male, Middle Aged, Polymers, Prospective Studies, Prosthesis Design, Single-Blind Method, Sirolimus, Treatment Outcome, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, bioabsorbable polymer, everolimus-eluting stents, PROMUS Element, SYNERGY, BIODEGRADABLE POLYMER, DURABLE POLYMER, ARTERY-DISEASE, STENOSIS, OUTCOMES, REVASCULARIZATION, MULTICENTER, THROMBOSIS, COVERAGE, LEADERS, Everolimus, 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology

Abstract:

This study sought to compare the safety and efficacy of 2 dose formulations of SYNERGY, a novel bioabsorbable polymer everolimus-eluting stent (EES) (Boston Scientific Corp., Natick, Massachusetts) compared with the durable polymer PROMUS Element EES (Boston Scientific Corp.).